These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 21177040

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Progression and treatment of HER2-positive breast cancer.
    Davoli A, Hocevar BA, Brown TL.
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
    Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H.
    Breast; 2008 Oct; 17(5):523-7. PubMed ID: 18534850
    [Abstract] [Full Text] [Related]

  • 7. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M, Bauer K, Pare M.
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [Abstract] [Full Text] [Related]

  • 8. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
    Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J.
    J Clin Oncol; 2012 Jul 20; 30(21):2601-8. PubMed ID: 22711854
    [Abstract] [Full Text] [Related]

  • 13. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X, Yuan Y, Gu Z, Shen K.
    Breast Cancer Res Treat; 2012 Aug 20; 134(3):957-67. PubMed ID: 22370627
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM, Lowe KA, Atwood M, Beatty JD.
    Breast J; 2010 Aug 20; 16(4):362-8. PubMed ID: 20443786
    [Abstract] [Full Text] [Related]

  • 16. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L.
    Cancer Res; 2010 Nov 01; 70(21):8852-62. PubMed ID: 20959472
    [Abstract] [Full Text] [Related]

  • 17. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, Murata Y, Yoshida S.
    Radiat Med; 2005 May 01; 23(3):189-94. PubMed ID: 15940066
    [Abstract] [Full Text] [Related]

  • 18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 19. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.
    Breast Cancer Res Treat; 2010 Jan 01; 119(1):119-26. PubMed ID: 19669409
    [Abstract] [Full Text] [Related]

  • 20. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ, Cui X, Hilsenbeck SG, Lee AV.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.